LIXA is focused on developing scalable antibiofilm technologies to treat antimicrobial resistance (AMR), for anyone, anything and anywhere. Our technologies disrupt both mature and immature biofilms and are compatible with most existing antimicrobials. We are open to partnerships to develop real solutions to AMR.
Location: Australia, Western Australia
Employees: 1-10
Total raised: $1.48M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 10.07.2026 | Melt Ventu... | melt.ventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.09.2022 | Series A | $1.48M | - |
Mentions in press and media 1
| Date | Title | Description |
| 01.09.2022 | The launch of a Lixa | Co-founder Angela Fonceca last night. Photo - CERI. At a crowded event last night held down at the Centre for Entrepreneurial Research and Innovation (CERI), a new bio-med company – Lixa – was launched, which has plans to beat back antibiot... |